ALTASCIENCES
30.5.2022 18:49:04 CEST | Business Wire | Press release
Altasciences announced today that it has been awarded a 2022 CRO Leadership Award in five categories, marking the seventh year the CRO/CDMO has been deemed a top performer by Clinical Leader and Life Science Leader.
Each year, Clinical Leader and Life Science Leader team up with ISR Reports to determine award recipients by assessing 50 CROs on more than 20 performance metrics in ISR’s annual Quality Benchmarking survey. This year, Altasciences received awards in the following categories: Capabilities, Compatibility, Expertise, Quality, and Reliability.
“Selecting the right CRO can make or break your project,” says Ed Miseta, Chief Editor for Clinical Leader. “It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for work ethic they exhibit in consistently meeting the needs of their drug development clients.”
Altasciences recognizes the importance of consistently exceeding the standards for excellence set by others in the industry, as well as their own. For more than 10 years, Altasciences has been transforming the traditional outsourcing paradigm, building a one-stop outsourcing solution that simplifies and accelerates the early phase drug development process for our partners. To that end, Altasciences is proud to have exceeded the expectations of small to large pharmaceutical companies, and will use the awards as further motivation to support educated, faster, integrated, and more complete early drug development decisions for their partners.
“To be recognized by the industry is not only an honor but a testament to the expertise of our people and the utmost care they show for both our partners and for those who seek the therapies we help develop,” says Chris Perkin, CEO at Altasciences. “To be acknowledged is a point of pride for our company, yes—but more importantly, it serves as a reminder that the more we build on our Capabilities, Compatibility, Expertise, Quality, and Reliability, the more our solutions can help our clients transform lives around the world.”
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005365/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Partners with Outpayce from Amadeus to Enable and Secure Payments for Airlines and Travel Merchants Worldwide7.4.2026 14:00:00 CEST | Press release
New integration brings AI-powered fraud prevention and chargeback protection to approve more bookings with confidence Riskified, a leader in ecommerce fraud and risk intelligence, today announced a partnership with Outpayce from Amadeus. This partnership boosts Outpayce’s trusted travel payment platform with Riskified’s AI-powered fraud prevention suite and Chargeback Guarantee model, creating a game-changing solution for airlines worldwide. The landscape of airline payments is evolving, and we're proud to share a major milestone that will reshape the way airlines approach fraud management. Outpayce from Amadeus is a global travel payments orchestrator and specialized fintech enabler, empowering airlines and travel merchants to streamline complex payment processes, optimize costs, and enhance customer experiences. Purpose-built for the travel industry, Outpayce delivers innovation, flexibility, and seamless integration within the Amadeus ecosystem, supporting secure, efficient, and sca
IQM and Real Asset Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form F-4 in Connection With Proposed Business Combination7.4.2026 13:12:00 CEST | Press release
IQM Finland Oy, a global leader in deployed on-premises, full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp., a special purpose acquisition company (Nasdaq: RAAQ) (“RAAQ”), today announced the confidential submission of the draft registration statement on Form F-4 (the “Registration Statement”) filed by IQM with the U.S. Securities and Exchange Commission (“SEC”) relating to their proposed business combination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407372076/en/ IQM Quantum Computers The submission of the Registration Statement marks an important milestone toward the completion of the proposed business combination, which will result in IQM becoming a publicly traded company. The business combination remains subject to approval by RAAQ shareholders, the Registration Statement being declared effective by the SEC, and other customary closin
Reckitt Accelerates Innovation with NIQ AI Insights, reporting up to 65% faster research7.4.2026 12:30:00 CEST | Press release
Case study shows faster development and stronger-performing concepts NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new results from Reckitt’s use of NIQ BASES AI Screener, demonstrating how AI-powered insights and synthetic data are transforming innovation speed and effectiveness. The case study highlights how Reckitt has accelerated concept development while improving performance outcomes—bringing more relevant products to market, faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407069246/en/ NIQ BASES AI Screener As companies face growing pressure to innovate quickly in an increasingly complex consumer landscape, traditional research and development cycles can slow decision-making. Reckitt’s adoption of AI-powered screening reflects a broader shift toward predictive, data-driven innovation—where teams can test, refine, and optimize ideas before investing in physical development. Key Resul
Lincotek Appoints New Global General Manager for Its Medical Division7.4.2026 10:08:00 CEST | Press release
Gianluca Fioravanti to lead business as it enhances its offer to OEMs Lincotek today announced the appointment of Gianluca Fioravanti as Global General Manager of its Medical Division - a global solution provider for the orthopedic market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407710572/en/ Gianluca Fioravanti, Global GM Lincotek’s Medical Division Reporting directly to Group CEO Andrea Colombo, Fioravanti assumed the role as of April 7 and will help drive the business forward. He will lead the development and execution of the company’s global growth strategy, while ensuring its seamless operational implementation across all regions. This strategic appointment reflects Lincotek’s commitment to enhance the value it delivers to customers, strengthening its ability to serve them better. Fioravanti brings more than 25 years of international experience to the Group, having held senior leadership roles across operation
Budweiser Honors 40 Years of FIFA World Cup™ Legacy with Limited-Edition Collectible Pack and Nostalgia-Themed Platform7.4.2026 09:00:00 CEST | Press release
The iconic brand marks its return as the Official Beer Sponsor of FIFA World Cup™ with anniversary packaging, a global film, and creative billboard tributes to football’s greatest moments Today, Budweiser is celebrating 40 years as the Official Beer Sponsor of the FIFA World Cup™ with the launch of the largest limited-edition collectible pack ever – the Budweiser® FIFA World Cup™ Anniversary Pack* – bringing to life 11 bold design tributes to every tournament since 1986, and the centerpiece of a new nostalgia driven global platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407304059/en/ Budweiser® FIFA World Cup™ Anniversary Pack Throughout history, Budweiser has played an important role in some of football’s most unforgettable celebrations, from last-minute goals to trophy lifts seen around the world. These moments of “Budstalgia” [Budweiser + nostalgia] are the inspiration for the brand’s newest platform, brought
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom